Clinical Response to Oral Tofacitinib in Pediatric Patients With Alopecia Areata

This study reviewed 10 pediatric cases of alopecia areata treated with oral tofacitinib at the Columbia dermatology clinic, involving patients aged 7 to 16 with varying subtypes and severities. All patients achieved full hair regrowth with doses of 5 mg to 10 mg twice daily, and no significant adverse effects were reported. The study suggested that oral tofacitinib was an effective and safe off-label treatment for pediatric alopecia areata, but acknowledged limitations such as the small sample size and lack of a control group. It recommended further large-scale, randomized trials to better understand the long-term efficacy and safety of tofacitinib in this population.